Related Experiment Video
Updated: Aug 11, 2026
10:39
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
miR-640 Enhances Abemaciclib Sensitivity by Suppressing CDK Inhibitor Resistance-Associated Genes in Breast Cancer
Ismail Mert Alkac1, Cigir Biray Avci1
1Department of Medical Biology, Ege University Medical School, İzmir, Turkey.
Journal of Cellular and Molecular Medicine
|August 10, 2026
Summary
MicroRNA-640 (miR-640) shows promise as a tumor suppressor in breast cancer. It resensitizes cells to CDK4/6 inhibitors by downregulating resistance genes, enhancing apoptosis and reducing metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- CDK4/6 inhibitors are crucial in breast cancer treatment but resistance limits efficacy.
- MicroRNAs (miRNAs) are key regulators of gene expression with therapeutic potential.
- Identifying novel therapeutic targets to overcome resistance is essential.
Purpose of the Study:
- To investigate miR-640's role in downregulating CDK4/6 inhibitor resistance genes.
- To evaluate the anti-cancer effects of miR-640, alone and with abemaciclib.
- To explore miR-640's impact on apoptosis, metastasis, and proliferation in breast cancer cells.
Main Methods:
- Bioinformatic analysis (GSE126125, miRDB, TargetScan, TargetMiner) to identify miR-640 targets.
- In vitro assays (MTT, Annexin V, cell cycle, wound healing) in MCF7 and MDA-MB-231 cells.
- Quantitative RT-qPCR to measure target gene expression after miR-640 transfection.
Main Results:
- miR-640 significantly downregulated key resistance genes (e.g., CDK4/6, CDKN2B, AURKA).
- Combination therapy (miR-640 + abemaciclib) enhanced apoptosis and inhibited migration.
- miR-640 induced cell line-specific cell cycle arrest (S/G2/M in MCF7, G0/G1 in MDA-MB-231).
Conclusions:
- miR-640 acts as a tumor suppressor by targeting resistance pathways.
- miR-640 resensitizes breast cancer cells to CDK4/6 inhibitors like abemaciclib.
- miR-640 represents a promising strategy for combination therapy in breast cancer.
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...